Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

A cohort study of the effect of traditional Chinese medicine combined with Western medicine standard treatment on survival of patients with liver metastasis of colorectal cancer.

Jiangyu Bian, Yuxing Sun, Wenting He et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15537

e15537 Background: Based on the results of our team's previous cohort study on metastatic colorectal cancer (mCRC), it can be seen that traditional Chines...

Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed/refractory (R/R) secondary central nervous system lymphoma (SCNSL).

Narendranath Epperla, Babatunde Adedokun, Hamza Hashmi et al. Jun 01, 2025 pp. 7024-7024 10.1200/jco.2025.43.16_suppl.7024

7024 Background: Axi-cel is an autologous anti-CD19 CAR T-cell therapy that demonstrated durable, long-term efficacy and manageable safety in R/R LBCL. Ho...

A phase I, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory CD19+ B-cell malignancies.

Jacob Randolph Garcia Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps2681

TPS2681 Background: Autologous, ex vivo-manufactured chimeric antigen receptor (CAR) T cells directed against CD19 have demonstrated clinical activity. Th...

Survival outcomes of whole pelvic vs. bladder-only radiation in muscle-invasive bladder cancer: A nationwide large-scale study.

Mohammad Arfat Ganiyani, Atulya Aman Khosla, Manas Pustake et al. Jun 01, 2025 pp. 4600-4600 10.1200/jco.2025.43.16_suppl.4600

4600 Background: Muscle-invasive bladder cancer (MIBC) is an aggressive malignancy traditionally managed with definitive surgery combined with systemic th...

Zongertinib in HER2-altered breast cancer: Preclinical activity and preliminary results from a phase Ia dose-escalation study.

David Berz, Frans Opdam, Daniela Maier et al. Jun 01, 2025 pp. 1023-1023 10.1200/jco.2025.43.16_suppl.1023

1023 Background: Preclinical studies have demonstrated that zongertinib, an irreversible TKI, selectively and potently inhibits oncogenic HER2 in a variet...

Improved survival with sodium-glucose cotransporter-2 inhibitors and immune checkpoint inhibitors in metastatic solid tumors.

Sara Young, Sean Dougherty, Hector Picon et al. Jun 01, 2025 pp. 2650-2650 10.1200/jco.2025.43.16_suppl.2650

2650 Background: Immune checkpoint inhibitors (ICI) are used in the first-line setting for the treatment of many advanced solid tumor malignancies. Patien...

A phase II, multicenter trial of the combination of chidamide and toripalimab in patients with advanced soft tissue sarcoma: Efficacy updates.

Xing Zhang, Ruiqing Peng, Peng Zhang et al. Jun 01, 2025 pp. 11560-11560 10.1200/jco.2025.43.16_suppl.11560

11560 Background: Chidamide is an oral subtype-selective histone deacetylase (HDAC) inhibitor which is effective on the patients with hematological tumors...

A real-world survival outcome comparison of a minority-rich population with DLBCL treated with CAR-T cell therapy vs. autologous stem cell transplant.

Ahmed Abbasi, Christopher Lawson, Melissa Rivas et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19016

e19016 Background: Chimeric Antigen Receptor (CAR)-T cell therapy has demonstrated superior efficacy compared to standard second-line treatments in relaps...

Impact of timing of diagnosis and breastfeeding on postpartum breast cancer outcomes.

Daniella Klebaner, Natalie Park, Carol Marquez et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12537

e12537 Background: Pregnancy-associated and postpartum breast cancers (PABC/PPBC) have a worse prognosis than other breast cancers. We hypothesized that p...

Impact of age on financial toxicity among breast cancer patients with resectable invasive breast cancer: A systematic review.

Sara Myers, Claire Morton, Paul A. Bain et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23194

e23194 Background: Financial toxicity (FT), the detrimental effect of treatment-related expenses on patient outcomes, is a significant issue related to br...

LEGEND: A phase 1/2 study of detalimogene voraplasmid (EG-70), an intravesical monotherapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC).

Jen-Jane Liu, Raj Satkunasivam, Rian J. Dickstein et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps4631

TPS4631 Background: High-risk NMIBC is generally treated with adjuvant intravesical Bacille Calmette-Guérin (BCG). However, ~50% of patients experience re...

Dendritic cell–based vaccines (KSD-101) against EBV-associated lymphoproliferative diseases: Results from an ongoing phase I clinical study.

Chunrui Li, Di Wang, Atsuhiko Hasegawa et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14515

e14515 Background: The Epstein–Barr Virus (EBV) infects over 95% of the global population. The WHO has definitively identified EBV as the first human tumo...

Perturbational single-cell RNA sequencing of patient tumors in Merkel cell and small cell lung carcinomas.

Curtis J. Perry, Alexander Frey, Yuewei Fei et al. Jun 01, 2025 pp. 2520-2520 10.1200/jco.2025.43.16_suppl.2520

2520 Background: Despite the transformational impact of immune checkpoint blockade, many cancer patients do not experience long-term survival. T cells wit...

Epigenetic and phenotypic signatures of T-cell response to blinatumomab in pediatric relapsed and refractory B-ALL.

Tyler G. Bruno, Grace Ward, Shala Carson et al. Jun 01, 2025 pp. 2528-2528 10.1200/jco.2025.43.16_suppl.2528

2528 Background: By forming an immunological synapse between T cells and tumor antigen, bispecific T cell engagers (BiTEs) like blinatumomab have shown gr...

The value of observerships abroad: Lessons from UA-MED supporting Ukrainian cancer care during the war.

Nataliya Kovalchuk, Andriy Beznosenko, Vitaliy Poylin et al. Jun 01, 2025 pp. 9036-9036 10.1200/jco.2025.43.16_suppl.9036

9036 Background: This study evaluates the influence of international observerships organized by the coalition of healthcare professionals from academic in...

Luspatercept in patients with lower-risk myelodysplastic syndromes (MDS): A systematic review and meta-analysis.

Abdulrahman Ahmad Alhajahjeh, Naira Woite, Alyssa Grimshaw et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18574

e18574 Background: Myelodysplastic syndromes (MDS) are bone marrow disorders often leading to anemia and transfusion dependence (TD). Luspatercept (Lusp)...

SHR-A1811 in patients (pts) with HER2-expressing advanced gynecological cancers (Gynecol C): A phase 2 study.

Beihua Kong, Jie Jiang, Gang Chen et al. Jun 01, 2025 pp. 5612-5612 10.1200/jco.2025.43.16_suppl.5612

5612 Background: SHR-A1811 is a novel an antibody-drug conjugate consisting of a humanized HER2-directed monoclonal antibody, cleavable tetrapeptide-based...

Real world data of precision medicine in the management of metastatic prostate cancer: A retrospective cohort study.

Awais Paracha, Margot Noyelle, Derek Tran et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17037

e17037 Background: Prostate cancer (PC) is the most diagnosed cancer in men in the United States with a 5-year relative survival rate for people with dist...

Virtual oncology collaborative tumor board using multiple artificial intelligence agents.

Jiasheng Wang, Sayan Mullick Chowdhury, Aziz Nazha Jun 01, 2025 pp. 1563-1563 10.1200/jco.2025.43.16_suppl.1563

1563 Background: Clinical guidelines are complex documents with tables and figures. Finding specific answers to questions within these guidelines can be c...

A novel virtual reality supportive care intervention (BMT-VR) for patients undergoing hematopoietic stem cell transplantation (HSCT): A pilot randomized clinical trial.

Hermioni L. Amonoo, Richard Newcomb, Lara Traeger et al. Jun 01, 2025 pp. 1504-1504 10.1200/jco.2025.43.16_suppl.1504

1504 Background: Patients with hematologic malignancies undergoing HSCT experience immense physical and psychological symptom burden during their extended...

Thromboembolic events in immunomodulatory drug (IMiD)–sparing regimens for patients with newly diagnosed multiple myeloma (NDMM).

Gliceida M. Galarza Fortuna, John McCarron, Elena Nazarenko et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19530

e19530 Background: Patients (pts) with NDMM treated with IMiD-based regimens have an increased risk of thromboembolic events (TE). In the MAIA study with...

Pelvic ultrasound: A missed opportunity for earlier detection of cervical cancer?

Tatiana Petrovick, Sophie Jabban, Amy Bleasdale et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17538

e17538 Background: Pelvic ultrasound is an imaging modality commonly used to detect and monitor gynecologic malignancy and has broad potential for use in...

Access to initial and subsequent indications of new oncology drugs: A US-Canada comparison.

Julie Patterson, Rayan Salih, Tyler Wagner et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23048

e23048 Background: Timelines of regulatory and health technology assessment (HTA) submissions and decisions vary by country, impacting patient access to n...

Phase 2 multicenter clinical trial to evaluate the safety and efficacy of abenacianine for injection (VGT-309), a tumor-targeted, intraoperative molecular imaging agent, for patients undergoing surgery for cancer in the lung.

Sunil Singhal, Luis J. Herrera, Gavin Michael Wright et al. Jun 01, 2025 pp. 3069-3069 10.1200/jco.2025.43.16_suppl.3069

3069 Background: Molecular targeted agents have revolutionized cancer diagnosis and treatment. Intraoperative molecular imaging (IMI) is a novel technique...

Beyond tumor-shed markers: AI driven tumor-educated polymorphonuclear granulocytes monitoring for multi-cancer early detection.

Rajan Datar, Massimo Cristofanilli, Darshana Patil et al. Jun 01, 2025 pp. 3060-3060 10.1200/jco.2025.43.16_suppl.3060

3060 Background: Tumor educated Polymorphonuclear Granulocytes (tPMNG) are a distinct phenotypic set of Neutrophils (N2) with corrupted programmed death p...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page